Non-small cell lung cancer
Conditions
Interventions
Four cycles of S-1 plus cisplatin as adjuvant chemotherapy
Sponsors
Division of Chest Surgery, Toho University Omori Medical Center
Division of Respirology and General Thoracic Surgery, NTT Medical Center Tokyo Department of Thoracic and Cardiovascular Surgery, Self-Defense Forces Central Hospital Division of Thoracic and Cardiovascular Surgery, Showa University School of Medicine Respiratory Disease Center, Showa University Northern Yokohama Hospital Division of Chest Surgery and Respiratory Medicine, Toho University Omori Medical Center Division of Surgery, Toho University Ohashi Medical Center Division of Surgery, T
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathologically diagnosed non-small cell lung cancer 2) pStage II-IIIA 3) Completely resected 4) Surgically treated patients 5) ND2a-2 or more 6) No prior therapy 7) ECOG Perfomance Status 0-1 8) Age 20-75 year-old 9) Able to oral intake 10) Adequate organ function 11) PaO2 >= 65mmHg or SpO2 >= 92% 12) Able to start within 8 weeks after the surgery 13) Written informed concent
Exclusion criteria
Exclusion criteria: 1) Drug allergy 2) Administering Flucytosine 3) Interstitial pneumonia 4) Serious medical complications 5) Diarrhea 6) Active double malignancies 7) Mental status 8) Pregnancy, breastfeeding or suspected of being pregnant 9) Pneumonectomy 10) Others judged by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Completion rate of four cycles of S-1 plus cisplatin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, time to treatment failure, relapse-free survival, toxicity, dose delivery, recurrent status | — |
Countries
Japan
Contacts
Public ContactAtsushi Sano
Toho University Omori Medical Center Chest Surgery
Outcome results
None listed